# US 2023/0414506 A1 · Peptide formulations and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0414506 A1
- Document ID: US20230414506A1
- Status: Published application
- Kind: A1
- Application number: 18/035,846
- Filed: 2021-11-03
- Published: 2023-12-28
- Earliest claimed: 2020-11-09
- Assignees: Realta Life Sciences, Inc.
- Applicants: Realta Life Sciences, Inc.
- Inventors: Neel K. KRISHNA; Kenji CUNNION
- Web page: https://patentgrep.com/patent/US20230414506A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides synthetic peptides. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to pharmaceutical formulations of the peptides including lipid-based formulations and formulations suitable for intravenous administration.

## Claims

### Claim 1

A composition comprising a therapeutically effective amount of SEQ ID NO: 3 and a lipid-based carrier.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the lipid-based carrier comprises lipid micelles.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the lipid-based carrier comprises a lipid emulsion.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the lipid-based carrier is present in an amount of about 10% w/v to about 20% w/v.

### Claim 5

A composition comprising a therapeutically effective amount of SEQ ID NO: 2 or SEQ ID NO: 3 and at least one excipient.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the at least one excipient is suitable for intravenous administration.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the at least one excipient is selected from the group consisting of a citrate, an ascorbate, amino acids, and combinations thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the citrate comprises sodium citrate.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the citrate is present in an amount of about 1% w/v to about 5% w/v.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the ascorbate comprises sodium ascorbate.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the ascorbate is present in an amount of about 1% w/v to about 5% w/v.

### Claim 12 (depends on 7)

The composition of claim 7, wherein the amino acids comprise L-methionine.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the amino acids are present in an amount of about 0.01% w/v to about 5% w/v.

### Claim 14 (depends on 1)

The compositions of claim 1, wherein SEQ ID NO: 2 or SEQ ID NO: 3 is present in an amount of about 0.001 to about 200 milligrams per kilogram (mg/kg) of body weight.

### Claim 15 (depends on 1)

The composition of claim 1, wherein SEQ ID NO: 2 and/or SEQ ID NO: 3 is present in an amount of about 5 to about 160 mg/kg.

### Claim 16 (depends on 1)

The composition of claim 1, wherein SEQ ID NO: 2 or SEQ ID NO: 3 is present in an amount of about 1 mg/ml to about 100 mg/ml.

### Claim 17 (depends on 1)

The composition of claim 1, wherein SEQ ID NO: 2 or SEQ ID NO: 3 is present in an amount of about 10 mg/ml to about 80 mg/ml.

### Claim 18 (depends on 1)

A method of altering cytokine expression comprising administering to a subject in need thereof a composition according to claim 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the administration comprises parenteral administration.

### Claim 20 (depends on 18)

The method of claim 18, wherein the administration comprises intravenous administration.

### Claim 21 (depends on 1)

A method of treating or preventing a disease or condition comprising administering to a subject in need thereof a composition according to claim 1.

### Claim 22 (depends on 21)

The method of claim 21, wherein the administration comprises parenteral administration.

### Claim 23 (depends on 21)

The method of claim 21, wherein the administration comprises intravenous administration.
